Research programme: ischaemic stroke therapy - Gedeon Richter/Merck KGaA
Latest Information Update: 25 Jul 2006
At a glance
- Originator Gedeon Richter; Merck KGaA
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 15 Aug 2001 Preclinical development for Stroke in Germany (Unknown route)
- 15 Aug 2001 Preclinical development for Stroke in Hungary (Unknown route)